AAAAAA

   
Results: 1-16 |
Results: 16
UFT and leucovorin in first-line chemotherapy for patients with metastaticgastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial
Authors: Ravaud, A Borner, M Schellens, JHM Geoffrois, L Schoffski, BP Kroon, K Wanders, J Hanauske, AR Fumoleau, P
Citation: A. Ravaud et al., UFT and leucovorin in first-line chemotherapy for patients with metastaticgastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial, EUR J CANC, 37(13), 2001, pp. 1642-1647
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
Authors: Schellens, JHM Dombernowsky, P Cassidy, J Epelbaum, R Dirix, L Cox, EH Wanders, J Calabresi, F Paridaens, R Monfardini, S Wolff, J Loos, WJ Verweij, J Pavlidis, N Hanauske, AR
Citation: Jhm. Schellens et al., Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9, ANTI-CANC D, 12(7), 2001, pp. 583-590
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors
Authors: Eskens, FALM Awada, A Cutler, DL de Jonge, MJA Luyten, GPM Faber, MN Statkevich, P Sparreboom, A Verweij, J Hanauske, AR Piccart, M
Citation: Falm. Eskens et al., Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors, J CL ONCOL, 19(4), 2001, pp. 1167-1175
Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours
Authors: Bos, AME de Vries, EGE Dombernovsky, P Aamdal, S Uges, DRA Schrijvers, D Wanders, J Roelvink, MWJ Hanauske, AR Bortini, S Capriati, A Crea, AEG Vermorken, JB
Citation: Ame. Bos et al., Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours, CANC CHEMOT, 48(5), 2001, pp. 361-369
In vitro activity of liposomal N(4)octadecyl-1-beta-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells
Authors: Schwendener, RA Friedl, K Depenbrock, H Schott, H Hanauske, AR
Citation: Ra. Schwendener et al., In vitro activity of liposomal N(4)octadecyl-1-beta-D-arabinofurano-sylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabino-furanocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells, INV NEW DR, 19(3), 2001, pp. 203-210
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors
Authors: Eskens, FALM Greim, GA van Zuylen, C Wolff, I Denis, LJ Planting, AST Muskiet, FA Wanders, J Barbet, NC Choi, L Capdeville, R Verweij, J Hanauske, AR Bruntsch, U
Citation: Falm. Eskens et al., Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors, CLIN CANC R, 6(5), 2000, pp. 1736-1743
Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG)
Authors: Sessa, C Wanders, J Roelvink, M Dombernowsky, P Nielsen, D Morant, R Drings, P Wissel, P Hanauske, AR
Citation: C. Sessa et al., Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG), ANN ONCOL, 11(2), 2000, pp. 207-210
Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors
Authors: van Groeningen, CJ Peters, GJ Schornagel, JH Gall, H Noordhuis, P de Vries, MJ Turner, SL Swart, MS Pinedo, HM Hanauske, AR Giaccone, G
Citation: Cj. Van Groeningen et al., Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors, J CL ONCOL, 18(14), 2000, pp. 2772-2779
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
Authors: Pavlidis, N Aamdal, S Awada, A Calvert, H Fumoleau, P Sorio, R Punt, C Verweij, J van Oosterom, A Morant, R Wanders, J Hanauske, AR
Citation: N. Pavlidis et al., Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG), CANC CHEMOT, 46(2), 2000, pp. 167-171
Preclinical activity of 17 beta-[N-[N '-(2-chloroethyl)-N '-nitrosocarbamoyl]-L-alanyl]-5 alpha-dihydrotesterone (E91) against tumour colony forming units and haematopoietic progenitor cells
Authors: Rank, P Peter, R Depenbrock, H Eisenbrand, G Schmid, P Pitzl, H Hanauske, AR
Citation: P. Rank et al., Preclinical activity of 17 beta-[N-[N '-(2-chloroethyl)-N '-nitrosocarbamoyl]-L-alanyl]-5 alpha-dihydrotesterone (E91) against tumour colony forming units and haematopoietic progenitor cells, EUR J CANC, 35(6), 1999, pp. 1009-1013
Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck - Results of a phase II study of the EORTC Early Clinical Studies Group
Authors: Schoffski, P Catimel, G Planting, AST Droz, JP Verweij, J Schrijvers, D Gras, L Schrijvers, A Wanders, J Hanauske, AR
Citation: P. Schoffski et al., Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck - Results of a phase II study of the EORTC Early Clinical Studies Group, ANN ONCOL, 10(1), 1999, pp. 119-122
UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer
Authors: Ravaud, A Borner, M Schellens, JHM Geoffrois, L Schoffski, P Wanders, J Hanauske, AR
Citation: A. Ravaud et al., UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer, ONCOLOGY-NY, 13(7), 1999, pp. 61-63
Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
Authors: Thodtmann, R Depenbrock, H Dumez, H Blatter, J Johnson, RD van Oosterom, A Hanauske, AR
Citation: R. Thodtmann et al., Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin, J CL ONCOL, 17(10), 1999, pp. 3009-3016
Reproducibility of metabolic measurements in malignant tumors using FDG PET
Authors: Weber, WA Ziegler, SI Thodtmann, R Hanauske, AR Schwaiger, M
Citation: Wa. Weber et al., Reproducibility of metabolic measurements in malignant tumors using FDG PET, J NUCL MED, 40(11), 1999, pp. 1771-1777
Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors
Authors: Thodtmann, R Depenbrock, H Blatter, J Johnson, RD van Oosterom, A Hanauske, AR
Citation: R. Thodtmann et al., Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors, SEMIN ONCOL, 26(2), 1999, pp. 89-93
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion
Authors: Rassmann, I Thodtmann, R Mross, M Huttmann, A Berdel, WE Manegold, C Fiebig, HH Kaeser-Frohlich, A Burk, K Hanauske, AR
Citation: I. Rassmann et al., Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion, INV NEW DR, 16(4), 1998, pp. 319-324
Risultati: 1-16 |